Semaglutide (Ozempic and Wegovy)
Overview
Semaglutide is a medication used for the treatment of type 2 diabetes and, in some cases, for weight management in individuals with obesity. It belongs to a class of drugs known as GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). Here are some key points about semaglutide:
-
Mechanism of Action: Semaglutide works by mimicking the action of the hormone GLP-1, which is involved in blood sugar regulation. It helps increase insulin secretion, thereby lowering blood sugar levels, and decreases glucagon secretion. It also slows gastric emptying, which contributes to its effect on appetite and weight loss.
-
Administration: It is typically administered via subcutaneous injection. There are different formulations available, including those for once-weekly injection. It’s important for patients to follow the specific dosing schedule prescribed by their healthcare provider.
-
Use in Diabetes Treatment: Semaglutide is primarily used to improve blood sugar control in adults with type 2 diabetes. It is often prescribed in combination with diet and exercise, and sometimes in conjunction with other diabetes medications.
-
Use in Weight Management: Semaglutide has also been shown to be effective in promoting weight loss in individuals with obesity or overweight, partly due to its appetite-suppressing effects. It is used under specific clinical conditions for weight management.
-
Side Effects: Common side effects of semaglutide can include nausea, vomiting, diarrhea, abdominal pain, and constipation. These gastrointestinal symptoms are generally most prominent at the start of treatment and may diminish over time.
-
Brand Names: Semaglutide is marketed under various brand names, including Ozempic® for diabetes treatment and Wegovy™ for weight management.
-
Generic Availability: Semaglutide was under patent protection. Generic versions would typically become available after the expiration of the patent, allowing other companies to produce and sell cheaper versions.
How does Semaglutide work?
Semaglutide News
Loading...
Do a live search of reviews and semiglutide in cancer PubMed now.
REVIEWS from PubMed – March 25, 2024 – Semaglutide (in title) AND Cancer (in title) AND Review
- GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence April 3, 2026Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressive mechanisms, including regulatory T-cells, myeloid-derived suppressor cells, and pro-inflammatory macrophages, can limit durable anti-tumor responses. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond metabolic comorbidity...Connor Frey
- The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation April 1, 2026No abstractChristo Albor
- Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? April 1, 2026Obesity is associated with increased risk of at least 13 adult cancer types and is the second most common cause of cancer (after tobacco) in many populations. Uncertainty about the extent to which intentional weight loss leads to reduced cancer risk represents a gap in knowledge. Evidence from bariatric surgery studies shows that sustained weight […]Andrew G Renehan
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity February 27, 2026Introduction: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use has ignited a debate regarding long-term safety, particularly concerning the risk of specific neoplasms and its ability to modulate cardiovascular health, not only as primary prevention […]Adriana Correra
- Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report February 23, 2026Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown robust efficacy in glycemic control, weight reduction, and cardiovascular protection, but concerns remain regarding rare adverse events such as acute pancreatitis. We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and […]Shao Chi Lo
- Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach February 13, 2026Background/Objectives: Nutraceuticals, including short-chain fatty acids (SCFAs) and antioxidants (AOXs), are nutrient-derived bioactive compounds considered as potential treatments for metabolic-associated steatotic liver disease (MASLD). However, in vitro studies of their effects are limited by inconsistent experimental conditions, including differences in cell lines, methods of steatosis induction, and culture media, and by reliance on qualitative rather […]Victoria E J M Palasantzas
- Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis February 11, 2026CONCLUSIONS: GLP-1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high-risk populations.Man Guo
- Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions February 11, 2026Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide. It can progress to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, cirrhosis and even hepatocellular carcinoma. However, most patients with non-cirrhotic MASLD die from extrahepatic causes, […]Lanlan Chen
- Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits December 19, 2025CONCLUSIONS: Semaglutide confers robust, consistent multisystem benefits-including cardiovascular, hepatic, and renal protection-supporting its role as a transformative, disease-modifying therapy for metabolic disease beyond diabetes and obesity management. These findings support using semaglutide as a comprehensive, disease-modifying therapy for complex metabolic disorders, guiding clinicians to integrate it into patient-centered care for multisystem benefits beyond glycemic and […]Naseem Eisa
- Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy December 17, 2025Lymphedema, traditionally viewed as a mechanical consequence of lymphatic obstruction, is increasingly recognized as a complex disorder rooted in metabolic dysfunction, particularly insulin resistance and chronic hyperinsulinemia. This paradigm-shifting hypothesis redefines lymphedema as a vascular complication driven by systemic metabolic stress, where prolonged hyperinsulinemia impairs lymphatic endothelial cell (LEC) function, triggering inflammation, oxidative stress, and […]Maher Monir Akl
- Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis December 8, 2025Glucagon-like peptide-1 (GLP-1) receptor agonists are essential for treating type 2 diabetes and promoting weight loss. Despite their therapeutic benefits, concerns have arisen regarding their potential association with pancreatic and thyroid cancers. This systematic review and meta-analysis examined the correlation between GLP-1 receptor agonists and cancer incidence in obese/overweight individuals, including both patients with diabetes […]Jaber H Jaradat
- Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis December 8, 2025CONCLUSION: GLP-1RAs may have little or no effect on risk for obesity-related cancers. Longer-term studies are needed to clarify potential risks or benefits.Albert Ko
- Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success December 5, 2025Peptide therapeutics are rapidly emerging as a new drug modality, bridging the gap between small molecules and biologics to target diseases such as diabetes, cancer, and cardiovascular disorders. Despite their advantages, challenges like metabolic instability, low permeability, and rapid clearance hinder their clinical development. This perspective focuses on addressing challenges in the metabolism of peptides […]Bin Ma
- The Involvement of the Peptidergic Systems in Breast Cancer Development November 27, 2025The current known data on the involvement of the peptidergic systems in breast cancer progression is overwhelmingly vast. Peptidergic systems are useful tools for imaging, diagnosis, prognosis and treatment of breast cancer. These systems play a crucial role in both basic and clinical breast cancer research by enabling the exploration of novel molecular mechanisms, signaling […]Manuel L Sánchez
- Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus November 26, 2025The complex bidirectional relationship between diabetes mellitus (DM) and oral cancer (OC) denotes that metabolic dysfunction and malignancy intersect at molecular, cellular, and systemic levels. This state-of-the-art review analyzes the most recent literature data on the multiple interconnected pathways linking DM and OC, including hyperinsulinemia/IGF-1 signaling, chronic hyperglycemia-induced cellular damage, persistent inflammation, immune dysfunction, and […]Viviana Elian
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review November 10, 2025CONCLUSIONS: A highly prevalent condition among adults worldwide, MASLD is associated with liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. First-line treatment includes behavioral modifications, including a weight-reducing diet, physical exercise, and avoidance of alcohol. Resmetirom and semaglutide are conditionally FDA-approved medications for the treatment of adults with MASH and moderate to advanced […]Herbert Tilg
- Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients October 25, 2025Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, delivering robust metabolic and cardiovascular benefits. However, their potential impact on tumorigenesis remains debated. Preclinical findings in rodents have suggested that GLP-1R activation may influence thyroid C-cells and pancreatic ducts, while human studies have yielded inconsistent cancer risk signals. This review […]Katarzyna Wawrzak-Pienkowska
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials September 24, 2025CONCLUSION: GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both […]Jimmy Wen
- The multifaceted effects of semaglutide: exploring its broad therapeutic applications September 4, 2025Semaglutide, a GLP-1 receptor agonist, is FDA-approved for managing type 2 diabetes (T2D) and reducing cardiovascular risk. Its off-label use in weight management and other conditions has grown, prompting a review of its benefits and risks. This review evaluates evidence on semaglutide's effects, highlighting its therapeutic potential beyond approved indications. Studies from 2021-2024 were reviewed […]Mesk Alkhatib
- GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management August 28, 2025Obesity is a well-established risk factor for both the incidence and poorer clinical outcomes of Breast Cancer (BC), particularly among hormone receptor-positive postmenopausal women. However, conventional weight loss interventions have yielded limited success in altering cancer prognosis. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have emerged as effective pharmacologic agents […]Juliana G Xande
Do a search of semaglutide and cancer PubMed now.
Recent PAPERS (33 total) from PubMed – March 25, 2024 – Semaglutide (in title) and Cancer (in title)
- Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer April 18, 2026CONCLUSION: Adjunct GLP-1 receptor agonist therapy was associated with reduced hysterectomy risk in EIN and EC, supporting prospective fertility-sparing studies.Tina Yi Jin Hsieh
- Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes April 13, 2026CONCLUSION: In patients with MASLD and T2D, MBS, and specifically RYGB, as compared to semaglutide, may drive a relatively increased risk of MALO despite protection against MACE, the first diagnosis of cirrhosis, heart failure, and OAC. Liver evaluation in individuals with T2D referred for MBS may help optimize their treatment.Weronika Stupalkowska
- GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence April 3, 2026Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressive mechanisms, including regulatory T-cells, myeloid-derived suppressor cells, and pro-inflammatory macrophages, can limit durable anti-tumor responses. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond metabolic comorbidity...Connor Frey
- Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? April 1, 2026Obesity is associated with increased risk of at least 13 adult cancer types and is the second most common cause of cancer (after tobacco) in many populations. Uncertainty about the extent to which intentional weight loss leads to reduced cancer risk represents a gap in knowledge. Evidence from bariatric surgery studies shows that sustained weight […]Andrew G Renehan
- The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation April 1, 2026No abstractChristo Albor
- Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer March 9, 2026CONCLUSIONS: This study demonstrated the potential CV benefit of GLP-1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.Cyrille K Cornelio
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity February 27, 2026Introduction: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use has ignited a debate regarding long-term safety, particularly concerning the risk of specific neoplasms and its ability to modulate cardiovascular health, not only as primary prevention […]Adriana Correra
- Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report February 23, 2026Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown robust efficacy in glycemic control, weight reduction, and cardiovascular protection, but concerns remain regarding rare adverse events such as acute pancreatitis. We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and […]Shao Chi Lo
- Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach February 13, 2026Background/Objectives: Nutraceuticals, including short-chain fatty acids (SCFAs) and antioxidants (AOXs), are nutrient-derived bioactive compounds considered as potential treatments for metabolic-associated steatotic liver disease (MASLD). However, in vitro studies of their effects are limited by inconsistent experimental conditions, including differences in cell lines, methods of steatosis induction, and culture media, and by reliance on qualitative rather […]Victoria E J M Palasantzas
- Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors February 12, 2026The use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for weight loss is increasing; implications in breast cancer survivors remain unclear. This retrospective cohort study evaluated treatment patterns, weight loss, and outcomes in breast cancer survivors receiving GLP1-RA at an academic institution. We evaluated patients with nonmetastatic [ductal carcinoma in situ (DCIS), stage 1-3] breast cancer […]Jasmine S Sukumar
- Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis February 11, 2026CONCLUSIONS: GLP-1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high-risk populations.Man Guo
- Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions February 11, 2026Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide. It can progress to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, cirrhosis and even hepatocellular carcinoma. However, most patients with non-cirrhotic MASLD die from extrahepatic causes, […]Lanlan Chen
- 18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot February 6, 2026We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment. Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration. Suspicions were confirmed by clinical […]Elizabeth Katherine Anna Triumbari
- Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study February 4, 2026CONCLUSION: While this study identifies a potential safety signal between semaglutide use and bile duct cancer, causality cannot be established. These findings underscore the importance of ongoing pharmacovigilance and the need for long-term observational studies and randomized controlled trials.Rimple Jeet Kaur
- Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling January 29, 2026Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven. This commentary equips clinicians with practical counseling strategies to reframe the "newness" narrative and address long-term safety concerns. We provide […]Priyansh P Shah
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis January 28, 2026Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the impact of GLP-1 RA therapy in this high-risk population is unknown. In this study, […]Sarina Ailawadi
- GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization January 3, 2026CONCLUSIONS: Patients with diabetes and cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Additionally, patients already on metformin and newly started on GLP-1 RA demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the […]Aditya Mahadevan
- Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report January 1, 2026Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advanced ALK+ non-small cell lung cancer (NSCLC) ever since its approved indication on November 17, 2017, based on the ALEX trial and its perceived well-tolerability. Lorlatinib, a third-generation ALK TKI, achieved 1L indication […]Alexandria T M Lee
- GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation December 26, 2025CONCLUSIONS: GLP-1 RA use during ICI therapy correlated with lower mortality, reduced acute care, fewer irAEs; ophthalmic signals warrant monitoring.Shan-Ho Chan
- Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits December 19, 2025CONCLUSIONS: Semaglutide confers robust, consistent multisystem benefits-including cardiovascular, hepatic, and renal protection-supporting its role as a transformative, disease-modifying therapy for metabolic disease beyond diabetes and obesity management. These findings support using semaglutide as a comprehensive, disease-modifying therapy for complex metabolic disorders, guiding clinicians to integrate it into patient-centered care for multisystem benefits beyond glycemic and […]Naseem Eisa
US Clinical Trials involving semaglutide
| NCT Number | Study Title | Study URL | Study Status | Sponsor | Locations |
|---|---|---|---|---|---|
| NCT05756764 | Anti-obesity Pharmacotherapy and Inflammation | https://clinicaltrials.gov/study/NCT05756764 | RECRUITING | Louisiana State University Health Sciences Center in New Orleans | LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana, 70112, United States|Ochsner Health System - Bioespecimen, New Orleans, Louisiana, 70121, United States |
| NCT05646199 | Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) | https://clinicaltrials.gov/study/NCT05646199 | NOT_YET_RECRUITING | University of Hull | Hull University Teaching Hospitals NHS Trust, Hull, HU32RW, United Kingdom |
| NCT05702905 | Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome | https://clinicaltrials.gov/study/NCT05702905 | RECRUITING | Peking University First Hospital | PekingUFH, Peking, Beijing, 100034, China |
| NCT05819853 | Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome | https://clinicaltrials.gov/study/NCT05819853 | RECRUITING | University of Colorado, Denver | University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora, Colorado, 80045, United States |